Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms

Hadir Marei, Angeliki Malliri

Research output: Contribution to journalArticlepeer-review

Abstract

Abnormal Rac1 signaling is linked to a number of debilitating human diseases,
including, cancer, cardiovascular diseases and neurodegenerative disorders. As such, Rac1 represents an attractive therapeutic target, yet the search for effective Rac1 inhibitors is still underway. Given the adverse effects associated with Rac1 signaling perturbation, cells have evolved several mechanisms to ensure the tight regulation of Rac1 signaling. Thus, characterizing these mechanisms can provide invaluable information regarding major
cellular events that lead to aberrant Rac1 signaling. Importantly, this information can be utilized to further facilitate the development of effective pharmacological modulators that can restore normal Rac1 signaling. In this review, we focus on the pathological role of Rac1 signaling, highlighting the benefits and potential drawbacks of targeting Rac1 in a clinical
setting. Additionally, we provide an overview of available compounds that target key Rac1 regulatory mechanisms and discuss future therapeutic avenues arising from our understanding of these mechanisms.
Original languageEnglish
JournalSmall GTPases
Early online date21 Jul 2016
DOIs
Publication statusPublished - 21 Jul 2016

Research Beacons, Institutes and Platforms

  • Manchester Cancer Research Centre

Fingerprint

Dive into the research topics of 'Rac1 in human diseases: The therapeutic potential of targeting Rac1 signaling regulatory mechanisms'. Together they form a unique fingerprint.

Cite this